Evidence map›Paper›PMID 41492187›Full record

ArticleJournal of cellular and molecular medicine2026

First LDLRAP1 and Recurrent LDLR Mutations in Tunisian Families With Familial Hypercholesterolemia.

Wirath Ben Ncir, Afif Ben-Mahmoud, Hamdi Frikha, Fatma Abdelhedi, Faten Hadj Kacem, Nabila Majdoub, Mouna Mnif, Hyung-Goo Kim, Leila Ammar Keskes, Jouke-Jan Hottenga

Abstract read
In one paragraph

Article in Journal of cellular and molecular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Wirath Ben NcirLaboratory of Human Molecular Genetics, Faculty of Medicine of Sfax, Sfax, Tunisia.ORCID https://orcid.org/0009-0008-4188-7265
Afif Ben-MahmoudNeurological Disorder Research Center, Qatar Biomedical Research Institute (QBRI), Hamad Bin Khalifa University (HBKU), Qatar Foundation, Doha, Qatar.
Hamdi FrikhaDepartment of Endocrinology, Hedi Chaker Hospital of Sfax, Sfax, Tunisia.
Fatma AbdelhediLaboratory of Human Molecular Genetics, Faculty of Medicine of Sfax, Sfax, Tunisia.
Faten Hadj KacemDepartment of Endocrinology, Hedi Chaker Hospital of Sfax, Sfax, Tunisia.
Nabila MajdoubDepartment of Endocrinology, Hedi Chaker Hospital of Sfax, Sfax, Tunisia.
Mouna MnifDepartment of Endocrinology, Hedi Chaker Hospital of Sfax, Sfax, Tunisia.
Hyung-Goo KimDepartment of Neurosurgery, Robert Wood Johnson Medical School, Rutgers, The State University of New Jersey, Piscataway, New Jersey, USA.
Leila Ammar KeskesLaboratory of Human Molecular Genetics, Faculty of Medicine of Sfax, Sfax, Tunisia.
Jouke-Jan HottengaNeurological Disorder Research Center, Qatar Biomedical Research Institute (QBRI), Hamad Bin Khalifa University (HBKU), Qatar Foundation, Doha, Qatar.

Funding

Qatar Biomedical Research Institute, Hamad Bin Khalifa University QB35
6 · The paper itself

Abstract

Familial hypercholesterolemia (FH) is a genetic disorder characterised by elevated plasma LDL-cholesterol, predisposing to premature atherosclerotic cardiovascular disease. Most cases follow an autosomal dominant pattern (ADH) caused by pathogenic variants in LDLR, APOB or PCSK9. In contrast, the rare autosomal recessive form (ARH) results from biallelic mutations in LDLRAP1, leading to defective LDL receptor-mediated endocytosis. Despite the high rate of consanguinity in Tunisia, LDLRAP1 variants have not yet been reported in this population. In this study, Whole Exome Sequencing of two consanguineous Tunisian families, identified distinct pathogenic variants. In the first family (FH-A), a recurrent LDLR splice-site variant (c.1845+1G>A) was detected in both heterozygous and homozygous states, consistent with an autosomal dominant inheritance pattern. In the second family (FH-B), a novel homozygous LDLRAP1 missense variant (c.161G>A; p.Gly54Asp) was identified, confirming autosomal recessive inheritance. In silico analyses using MutationTaster, DynaMut2, MUpro, DDGun, NetSurfP-2.0, ConSurf and PyMOL predicted that the p.Gly54Asp substitution destabilises the PTB domain of LDLRAP1 by disrupting key hydrogen bonds and hydrophobic interactions, thereby likely impairing LDLR internalisation. According to ACMG guidelines, this variant is classified as likely pathogenic. Clinically, ARH patients exhibited early-onset xanthomas and an unusual quadricuspid aortic valve (QAV). Targeted analysis of valvulogenesis genes (NOTCH1, GATA4, NKX2-5, TBX5, AGTR1, BMP2) revealed no co-segregating pathogenic variants, suggesting that QAV may result from embryonic LDL accumulation disrupting Notch1 signalling rather than a monogenic defect. Comparison with other ADH Tunisian families carrying the same LDLR mutation showed phenotypic variability, likely influenced by genetic modifiers, treatment response and environmental factors. These findings provide the first evidence of LDLRAP1-associated ARH in Tunisia and highlight the genetic heterogeneity of FH, emphasising the importance of integrating molecular, structural and functional analyses for accurate diagnosis, personalised management and early prevention.

Indexed as

Adaptor Proteins, Signal TransducingHyperlipoproteinemia Type IIMutationReceptors, LDLAdultConsanguinityExome SequencingFemaleHumansMaleMiddle AgedPedigreeTunisiaAdaptor Proteins, Signal TransducingLDLRAP1 protein, humanLDLR protein, humanReceptors, LDLADHARHautosomal dominant hypercholesterolemiaautosomal recessive hypercholesterolemiafamilial hypercholesterolemiaLDLRLDLRAP1

Identifiers

PMID41492187
PMCPMC12771596

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.